Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Cimiracemoside C (Cimicifugoside M) is an active component of Cimicifuga racemosa. It activates AMPK and has the potential activity against diabetes.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
1 mg | 在庫あり | ¥ 16,000 | |||
5 mg | 在庫あり | ¥ 38,000 | |||
10 mg | 在庫あり | ¥ 65,000 | |||
25 mg | 在庫あり | ¥ 110,000 | |||
50 mg | 在庫あり | ¥ 158,000 | |||
100 mg | 在庫あり | ¥ 220,000 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 56,000 |
説明 | Cimiracemoside C (Cimicifugoside M) is an active component of Cimicifuga racemosa. It activates AMPK and has the potential activity against diabetes. |
In vitro | Ze 450 and some of its components (23-epi-26-deoxyactein, protopine and Cimiracemoside C) were investigated in vitro for their effects on AMP-activated protein kinase (AMPK) compared to metformin in HepaRG cells. Ze 450 (given orally (PO) and intraperitonally (IP)), metformin (PO) and controls were given over 7 days to 68 male ob/ob mice. Glucose and insulin concentrations were measured at baseline and during an oral glucose tolerance test (OGTT). Ze 450 and its components activated AMPK to the same extent as metformin. In mice, Ze 450 (PO/IP) decreased significantly average daily and cumulative weight gain, average daily food and water intake, while metformin had no effect. In contrast to metformin, PO Ze 450 virtually did not change maximum glucose levels during OGTT, however, prolonged elimination. Ze 450 administered PO and IP decreased significantly post-stimulated insulin, whereas metformin did not. HOMA-IR index of insulin resistance improved significantly after IP and PO Ze 450 and slightly after metformin. In summary, the results demonstrate that Ze 450 reduced significantly body weight, plasma glucose, improved glucose metabolism and insulin sensitivity in diabetic ob/ob mice. In vitro experiments suggest that part of the effects may be related to AMPK activation. |
植物由来 |
別名 | Cimicifugoside M |
分子量 | 620.81 |
分子式 | C35H56O9 |
CAS No. | 256925-92-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 6.21 mg/mL (10 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Cimiracemoside C 256925-92-5 Chromatin/Epigenetic PI3K/Akt/mTOR signaling AMPK AMP-activated protein kinase inhibit Inhibitor Cimicifugoside M inhibitor